Ready to press o
Ready to fill þ
Ixazomib functions by obstructing protein degradation through the inhibition of the 20S catalytic subunit of the 26S proteasome. Specifically, at lower concentrations, MLN2238 targets and inhibits the β5 chymotrypsin-like subunit, which is responsible for cleaving proteins after hydrophobic residues. This mechanism effectively hinders the proteasome’s ability to degrade proteins
Ixazomib is used in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma that has been previously treated with at least one prior therapy. This combination therapy has been designated as an orphan drug for this specific use.